Patritumab, alone or combined with an anti-EGFR mAb, inhibited non-small cell lung cancer (NSCLC) xenografts growth, including wild-type and TKI-resistant EGFR models[65]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.